U.S. Markets open in 4 hrs 11 mins
  • S&P Futures

    4,170.75
    +13.00 (+0.31%)
     
  • Dow Futures

    34,330.00
    +74.00 (+0.22%)
     
  • Nasdaq Futures

    13,404.00
    +100.50 (+0.76%)
     
  • Russell 2000 Futures

    2,233.30
    +7.80 (+0.35%)
     
  • Crude Oil

    66.69
    +0.42 (+0.63%)
     
  • Gold

    1,870.10
    +2.50 (+0.13%)
     
  • Silver

    28.66
    +0.39 (+1.37%)
     
  • EUR/USD

    1.2219
    +0.0062 (+0.5132%)
     
  • 10-Yr Bond

    1.6400
    0.0000 (0.00%)
     
  • Vix

    19.32
    +0.51 (+2.71%)
     
  • GBP/USD

    1.4213
    +0.0076 (+0.5344%)
     
  • USD/JPY

    108.8700
    -0.3300 (-0.3022%)
     
  • BTC-USD

    44,786.32
    -219.34 (-0.49%)
     
  • CMC Crypto 200

    1,243.69
    +45.78 (+3.82%)
     
  • FTSE 100

    7,056.10
    +23.25 (+0.33%)
     
  • Nikkei 225

    28,406.84
    +582.01 (+2.09%)
     

Affimed To Study AFM24/SNK-01 Combo In Solid Tumor Settings

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • The FDA has signed off an investigational new drug application for Affimed NV (NASDAQ: AFMD) and NKMax America co-sponsored Phase 1/2a dose escalation and expansion study to evaluate AFM24 and SNK-01 in EGFR-expressing solid tumors.

  • The Phase 1/2a study will be an open-label, non-randomized, multi-center, US-only, dose-escalation trial to evaluate the combination, with the primary objective to establish the safety and the recommended Phase 2 dose.

  • The Phase 1 part will also assess pharmacokinetics, pharmacodynamics, and preliminary activity.

  • The Phase 2a portion of the study will evaluate the preliminary efficacy of AFM24 in patients with select solid tumor subtypes.

  • Credit Suisse analyst Brad Canino initiates coverage on Affimed with an Outperform rating and a Price Target of $15.

  • Price Action: AFMD shares are up 6.5% at $7.82 in the market trading session on the last check Wednesday.

Latest Ratings for AFMD

Mar 2021

Credit Suisse

Initiates Coverage On

Outperform

Mar 2021

Wells Fargo

Maintains

Overweight

Mar 2021

SVB Leerink

Maintains

Outperform

View More Analyst Ratings for AFMD
View the Latest Analyst Ratings

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.